inVentiv Health has renamed its New Jersey, US-based clinical research organisation (CRO) PharmaNet/I3 as inVentiv Health Clinical.
The decision was made in order to align the CRO business with the company’s broader commercial and consulting services.
“As a top global CRO, renaming ourselves inVentiv Health Clinical demonstrates a company-wide commitment to our clinical clients, who will benefit from seamless, global access to a more robust range of services,” commented inVentiv Health’s CEO Paul Meister.
“Clients can now access broad inVentiv talent with expertise across the product life cycle to deliver tailored solutions from product development through commercialisation.”
The CRO, which offers phase I/II/III and late stage clinical development as well as clinical staffing services, is led by Raymond Hill, who was appointed in December 2012.
“By connecting clinical research and staffing capabilities to consulting and commercial services, inVentiv can offer fully integrated solutions to pharmaceutical, biotechnology, generic drug and medical device companies in a way that cannot be matched by any other CRO in the industry,” said Hill.
“One example is our ability to assist clients in late-stage trials by tapping both digital and adherence experts from other inVentiv companies.
“Through this approach we can help our clients simplify complex health economics and outcomes research trials.
“Healthcare companies are continuing to increase their reliance on CROs.
“With 7,000 employees in more than 36 countries across the world, inVentiv Health Clinical has the breadth of experience in geographies and the necessary therapeutic expertise to meet the challenges that our clients are facing,” he finished.